Catherine Hollingsworth

Would-be Biogen Buyer's Path Clear, Elan in Tysabri Trouble

Sep. 9, 2009

Opexa Gets Boost on Positive Analysis of Tovaxin MS Data

Sep. 9, 2009

Shares of Opexa Therapeutics Inc. soared 270 percent Tuesday on news of a positive complete analysis of its Phase IIb drug for multiple sclerosis, Tovaxin. (BioWorld Today)

Would-be Biogen Buyer's Path Clear, Elan in Tysabri Trouble

Sep. 8, 2009

By Catherine Hollingsworth

Algeta's Alpharadin Bayer Deal: $800M Fixes Thorium Headache

Sep. 4, 2009

By Catherine Hollingsworth

Knopp Phase II Data Piques Interest of Potential Partner

Sep. 3, 2009

By Catherine Hollingsworth

$210M Deal Gives Endo Rights to Testosterone Gel Fortesta

Sep. 2, 2009

By Catherine Hollingsworth

Novavax Will Need More Cash to Push VLP Vaccine Farther

Sep. 2, 2009

By Catherine Hollingsworth

Pozen Gets $10M Payday for FDA Accepting Vimovo Filing

Sep. 1, 2009

By Catherine Hollingsworth

Trubion, Facet Joining Forces on Early-Stage Leukemia Drug

Aug. 31, 2009

By Catherine Hollingsworth

Trubion Pharmaceuticals Inc. has entered collaboration with Facet Biotech Corp. to jointly develop Phase I TRU-016 for chronic lymphocytic leukemia, in a deal worth up to $206.5 million. (BioWorld Today)